The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo
dc.creator | Sychev D.A. | |
dc.creator | Ashraf G.M. | |
dc.creator | Svistunov A.A. | |
dc.creator | Maksimov M.L. | |
dc.creator | Tarasov V.V. | |
dc.creator | Chubarev V.N. | |
dc.creator | Otdelenov V.A. | |
dc.creator | Denisenko N.P. | |
dc.creator | Barreto G.E. | |
dc.creator | Aliev G. | |
dc.date.accessioned | 2020-09-02T22:28:49Z | |
dc.date.accessioned | 2022-11-08T20:21:06Z | |
dc.date.available | 2020-09-02T22:28:49Z | |
dc.date.available | 2022-11-08T20:21:06Z | |
dc.date.created | 2020-09-02T22:28:49Z | |
dc.date.issued | 2018 | |
dc.identifier | 12, , 1147-1156 | |
dc.identifier | 11778881 | |
dc.identifier | https://hdl.handle.net/20.500.12728/6356 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5143882 | |
dc.language | en | |
dc.publisher | Dove Medical Press Ltd. | |
dc.subject | Cytochrome CYP450 | |
dc.subject | Drug interaction | |
dc.subject | Drug metabolism | |
dc.subject | Phenotyping | |
dc.subject | alprazolam | |
dc.subject | atorvastatin | |
dc.subject | caffeine | |
dc.subject | celecoxib | |
dc.subject | clozapine | |
dc.subject | codeine | |
dc.subject | cytochrome P450 1A2 | |
dc.subject | cytochrome P450 2C19 | |
dc.subject | cytochrome P450 2C9 | |
dc.subject | cytochrome P450 2D6 | |
dc.subject | cytochrome P450 3A4 | |
dc.subject | dextromethorphan | |
dc.subject | diazepam | |
dc.subject | hexobarbital | |
dc.subject | losartan | |
dc.subject | metoprolol | |
dc.subject | nortriptyline | |
dc.subject | omeprazole | |
dc.subject | pantoprazole | |
dc.subject | paracetamol | |
dc.subject | phenacetin | |
dc.subject | phenytoin | |
dc.subject | pravastatin | |
dc.subject | propafenone | |
dc.subject | testosterone | |
dc.subject | theophylline | |
dc.subject | tolbutamide | |
dc.subject | unindexed drug | |
dc.subject | warfarin | |
dc.subject | zidovudine | |
dc.subject | 6 beta-hydroxycortisol | |
dc.subject | cytochrome P450 | |
dc.subject | hydrocortisone | |
dc.subject | isoenzyme | |
dc.subject | drug metabolism | |
dc.subject | drug transformation | |
dc.subject | enzyme activity | |
dc.subject | enzyme inhibition | |
dc.subject | enzyme specificity | |
dc.subject | human | |
dc.subject | hydrophilicity | |
dc.subject | hydrophobicity | |
dc.subject | in vitro study | |
dc.subject | in vivo study | |
dc.subject | phenotype | |
dc.subject | prediction | |
dc.subject | protein expression | |
dc.subject | protein function | |
dc.subject | Review | |
dc.subject | single nucleotide polymorphism | |
dc.subject | analogs and derivatives | |
dc.subject | biotransformation | |
dc.subject | drug interaction | |
dc.subject | metabolism | |
dc.subject | Biotransformation | |
dc.subject | Cytochrome P-450 Enzyme System | |
dc.subject | Drug Interactions | |
dc.subject | Humans | |
dc.subject | Hydrocortisone | |
dc.subject | Isoenzymes | |
dc.subject | Phenotype | |
dc.title | The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo | |
dc.type | Review |